Patents Examined by Dennis Heyer
  • Pharmaceutical compositions with enhanced stability
    Patent number: 10646572
    Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 12, 2020
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, Benjamin Chien
  • Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
    Patent number: 10632120
    Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: April 28, 2020
    Assignee: Emory University
    Inventors: Michael G. Natchus, Richard Arrendale, Dennis Liotta, Ketan Desai, Hyunsuk Shim
  • Liquid pharmaceutical composition
    Patent number: 10624879
    Abstract: The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 21, 2020
    Assignee: FERRING INTERNATIONAL CENTER S.A.
    Inventors: Bong Gil Nam, Byeung Jun Lee, Shunji Jin
  • Emulsion formulations of an NK-1 receptor antagonist and uses thereof
    Patent number: 10624850
    Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 21, 2020
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Han Han
  • Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas
    Patent number: 10617688
    Abstract: The present invention pertains to the technological sector of the pharmaceutical industry and, more specifically, refers to a second use composition intended for the treatment of a dermatology condition called Poikiloderma of Civatte. The solution proposed in this document is the use of a topical composition containing any substance alone or in combination from the pharmacological group of alpha-adrenergic receptor agonists in therapeutic quantities to treat color of the lesions of Poikiloderma of Civatte. The application of this composition for the condition of Poikiloderma of Civatte results in significant improvement of the color of the skin lesions, also improving the vascular component present in this condition and can be associated with other compounds.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: April 14, 2020
    Inventor: Doris Maria Hexsel
  • Composition including indoprofen and use thereof
    Patent number: 10610515
    Abstract: A method of increasing PGC-1? expression in a mammalian cell, the method comprising administering an effective amount of indoprofen, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: April 7, 2020
    Assignees: SAMSUNG ELECTRONICS CO., LTD., RESEARCH & BUSINESS FOUNDATION, SUNGKYUNKWAN UNIVERSITY
    Inventors: Sungchun Cho, Jongsun Kang, Sangchul Park, Yunil Lee, Hyebeen Kim, Hyeyoung Lee
  • Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
    Patent number: 10596131
    Abstract: Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 51% to 99.5% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 49% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 24, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Method and compositions for treating viral infections
    Patent number: 10596186
    Abstract: A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae, Flaviviridae or Togaviriade family, is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: March 24, 2020
    Assignee: PHOENIX BIOTECHNOLOGY, INC.
    Inventors: Robert A. Newman, Otis C. Addington
  • Epithelial quantitation of histologically normal prostate tissue predicts the presence of cancer in tissue biopsies
    Patent number: 10598664
    Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial percentage of the tissue, wherein an epithelial percentage greater than 39% indicates the presence of prostate cancer or a prostate cancer field defect.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 24, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: David Frazier Jarrard, Bing Yang
  • Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
    Patent number: 10596128
    Abstract: Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the S-enantiomer are formulated to control ketone body levels in a subject. The non-racemic mixture of BHB is enriched with the S-enantiomer to modulate the effect of ketone bodies in the subject and control the rate at which ketosis is achieved. In some aspects a composition for controlling ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, wherein the non-racemic mixture contains from about 52% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer and from about 48% to about 1% by enantiomeric equivalents of R-beta-hydroxybutyrate enantiomer.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 24, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
    Patent number: 10596129
    Abstract: Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 55% to 98% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 45% to about 2% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: March 24, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
    Patent number: 10596130
    Abstract: Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the S-enantiomer are formulated to control ketone body levels in a subject. The non-racemic mixture of BHB is enriched with the S-enantiomer to modulate the effect of ketone bodies in the subject and control the rate at which ketosis is achieved. In some aspects a composition for controlling ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, wherein the non-racemic mixture contains from about 52% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer and from about 48% to about 1% by enantiomeric equivalents of R-beta-hydroxybutyrate enantiomer.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: March 24, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Compositions and methods for cerumen removal
    Patent number: 10596106
    Abstract: Systems and methods for removal of human cerumen are provided. A composition for removal of cerumen includes at least one cerumenolytically acceptable active agent and an otologically acceptable vehicle. The cerumenolytically acceptable active agent may be an alpha-hydroxy acid (AHA). Exemplary AHA may include, but are not limited to, glycolic acid, tartronic acid, lactic acid, malic acid and any derivative or mixture thereof. The otologically acceptable vehicle may be sodium or potassium salts of bicarbonate aqueous buffer. Yet further, the otologically acceptable vehicle may contain sodium docusate. Cerumen may be removed and/or a cerumen impaction may be treated by administering to a patient in need thereof a composition comprising an AHA and an otologically acceptable vehicle.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 24, 2020
    Assignee: Eosera, Inc.
    Inventors: Joe Griffin, Eric Anderson
  • Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
    Patent number: 10596190
    Abstract: Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: March 24, 2020
    Assignee: Oregon Health & Science University
    Inventor: Edward A. Neuwelt
  • Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
    Patent number: 10588876
    Abstract: Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 55% to 98% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 45% to about 2% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 17, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Method of protecting field corn from damage by a plant pathogen
    Patent number: 10575524
    Abstract: The present invention can provide a method having superior safety for protecting field corn from damage by a plant pathogen. The method includes a step of applying mefentrifluconazole to foliage of field corn, seeds of field corn or a soil of the cultivation area of field corn, wherein the application rate of mefentrifluconazole is 20 to 500 g per hectare of cultivation area.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: March 3, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yoshinao Sada
  • Method of treating renal system damage
    Patent number: 10568857
    Abstract: Methods of treating the side effects of a toxic medical therapy using nitrated lipids are disclosed herein. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: February 25, 2020
    Assignee: The University of Utah Research Foundation
    Inventor: Tianxin Yang
  • Methods for treating neuroblastoma
    Patent number: 10561651
    Abstract: Methods of treating neuroblastoma associated with a deregulated protein kinase activity are disclosed. The treatment may include administration of substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts therefor, as degined in the specification.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: February 18, 2020
    Assignees: IGNYTA, INC., NERVIANO MEDICAL SCIENCES, S.R.L.
    Inventors: Jonathan Lim, Elena Ardini, Maria Menichincheri
  • Ophthalmic compositions and methods of use
    Patent number: 10555947
    Abstract: The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist; (ii) a corticosteroid; (iii) a lymphocyte function-associated antigen antagonist; (iv) a non-steroidal anti-inflammatory drug (NSAID); (v) a sodium channel blocker; and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: February 11, 2020
    Assignee: OCUGEN, INC.
    Inventors: Shankar Musunuri, Sandeep Jain, Rasappa Arumugham, Arun K. Upadhyay, Matthew Nudell, Gopalam Somasekhar
  • Topical formulation and method for preventing or treating acne
    Patent number: 10548862
    Abstract: Provided is a topical formulation for preventing or treating acne, including a benzenesulfonamide derivative, and a pharmaceutically or cosmetically acceptable excipient. Also provided is a method for preventing or treating acne, including applying the topical formulation on skin of a subject in need thereof.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 4, 2020
    Assignees: Gongwin Biopharm Holdings Co., Ltd.
    Inventors: Chuan-Ching Yang, Mao-Yuan Lin, Tai-Jung Wu, Chi-Chiang Tu, Shun-Chi Wu